In the United States, attaining formulary position and negotiating prices have become increasingly complex and competitive, especially in light of new guidelines under the Affordable Care Act (ACA). Success guarantees that treatments reach patients — and that brands meet or exceed revenue expectations. This report focuses exclusively on US government reimbursement strategy and trends. This study provides actionable insights — drawn from the data and experiences of top-performing life science executives — for winning and maintaining formulary position. Data show US government reimbursement pricing systems and payer relationship management strategies.
Use patient-reported outcomes to guide product development and improve market access initiatives. Leverage the healthcare consumer perspective to strengthen product value propositions during regulatory approval and reimbursement discussions and to gain insight to drive commercial potential.
In response to payers’ increased pressure on pharmaceutical and medical device prices, the industry is leveraging new research to bolster the value proposition for new drugs and therapies. However, simply developing this information is not enough. Managed markets teams are the effective and efficient solution to convey key data to payers.
Medical Device companies are increasingly under pressure to meet payer demands. To succeed in this environment, device companies arm themselves with health economics data to satisfy payer requirements and maintain optimal price levels.
Big Data is forcing the pharmaceutical and medical device industries to re-examine every research channel for opportunities to improve various departments’ work. Harness Big Data to increase efficiency of data analysis during prospective and retrospective studies and better meet patient needs through improved market intelligence.
Learn strategies for building an efficient HOL team and discover best practices to get the best results out of payer interactions.
Use this report to win reimbursement, align HEOR with corporate objectives, and allocate resources across health economics priorities.
Explore pharmaceutical launch sequencing factors, manage the impact of reference pricing and prepare for future growth in key emerging markets.
Win reimbursement, improve payer communication and build a world-class managed markets function.